[The effect of cytostatic therapy on hemodynamics (author's transl)].
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001776:Blood Circulation Time; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002306:Cardiac Volume / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003348:Cortisone / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D004077:Digoxin / Q000008:administration & dosage; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000188:drug therapy; D006334:Heart Function Tests; D006439:Hemodynamics / Q000187:drug effects*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012737:Sex Factors; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D004077:Digoxin; D003348:Cortisone; D003630:Daunorubicin
Beeinflussung der Hämodynamik durch Zytostatika.